πŸ‡ΊπŸ‡Έ FDA
Patent

US 11584758

RIP1K inhibitors

granted A61KA61K9/0053A61P

Quick answer

US patent 11584758 (RIP1K inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K9/0053, A61P, A61P17/00, A61P25/00